Clinical Trials Browser

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

NCT01331941 2017-11-06

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Phase 1 Completed

35 enrolled

Genitourinary

Kidney Diseases, Renal Insufficiency

NCT01599013 2015-12-08

JASINT1

Phase 2 Completed

69 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

NCT00418366 2015-08-19

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Phase 1 Completed

24 enrolled

GenitourinaryLymphoid

Kidney Failure, Chronic, Lymphoma, Follicular, Renal Insufficiency

NCT01273597 2013-01-18

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands

Completed

60 enrolled 11 charts

Genitourinary

Kidney Failure, Chronic, Neoplasm Metastasis, Renal Insufficiency

Clinical Trials

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

DREAMM12

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

JASINT1

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands